Cailin Conner

DocwireNews

Frontiers in Endocrinology published a systematic review and meta-analysis, which found the use sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of prescription medicines that are used with diet and exercise to lower blood sugar in adults with type 2 diabetes mellitus (TD2M), was associated with a 34% decreased risk of developing gout among patients with T2DM.To conduct this study, a systematic review and meta-analysis were carried out in accordance with the PRISMA 2020 guidelines. Articles published between January 1, 2000, and December 31, 2022, were searched using the PubMed and Web of Science databases. The primary endpoint of interest was the incidence of gout, including gout flares, gout events, initiation of uric acid-lowering therapy, and use of anti-gout drugs, in T2DM patients using SGLT2 inhibitors compared with those not using SGLT2 inhibitors. The researchers used a random-effects model to estimate the combined hazard ratio (HR) along with a 95% CI in order to assess the relationship between the use of SGLT2 inhibitors and the risk of developing gout.The study included 2 prospective post-hoc analyses of randomized controlled trials and 5 retrospective cohort studies utilizing electronic medical record-linkage. The analysis demonstrated a significant reduction in the risk of developing gout among patients with T2DM using SGLT2 inhibitors compared with those not using SGLT2 inhibitors. The pooled HR was estimated at 0.66 (95% CI, 0.57-0.76), indicating a 34% decreased risk of gout associated with SGLT2 inhibitor use.The precise mechanisms responsible for the utilization of SGLT2 inhibitor and its potential for reducing gout risk remain unknown. As noted by the authors, these therapeutics function by inhibiting the reabsorption of glucose and sodium in the kidney&rsquo;s proximal tubule. This action results in elevated excretion of glucose and sodium through urine, as well as an increase in urinary volume. Consequently, blood glucose levels are reduced. Additionally, the augmented urinary volume has the potential to improve the elimination of uric acid, offering a plausible explanation for the decrease in blood uric acid levels. Therefore, the authors posit that it is &ldquo;a rational hypothesis that SGLT2 inhibitor reduces blood uric acid levels by enhancing urinary excretion of uric acid. Thus, the risk of gout is reduced after the use of SGLT2 inhibitors.&rdquo;To conclude their review, the authors emphasized the need for randomized controlled trials and real-world evidence are necessary to verify whether there exists a consistent pattern across the SGLT2 inhibitor class in reducing the risk of gout among patients with T2DM.&nbsp;Source: <a href="https://www.frontiersin.org/articles/10.3389/fendo.2023.1158153/full" target="_blank" rel="noopener">Frontiers in Endocrinology</a>

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Study Links SGLT2 Inhibitor Use to Lower Risk of Gout in Patients With Type 2 Diabetes

Gout

A systematic review and meta-analysis found that the use of SGLT2 inhibitors in patients with type 2 diabetes was associated with a 34% decreased risk of developing gout.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe